Resistant starch trial in NAFLD patients, Shanghai, China
252 gut metagenome samples from a randomized, placebo-controlled, double-blinded clinical trial in Shanghai, China, testing 16-week resistant starch (prebiotic/fibre) intervention in patients with NAFLD. machine-written summary
252 samples · 252 runs · CN · Age unknown · 2022 · 6.17 Gbp / sample · cohort Risk assessment with gut microbiome and metabolite
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 2,215 sample values (collection date, country, intervention, latitude, location locality, location region, longitude, subject id) |
| ✓ Abstract / description | 504 sample values (health condition, health condition detail) |
| ○ Full text | read; no usable statement or table · PMC10408196, PMC11730835, PMC9746350 |
| ✓ Supplementary tables | 8 sample values (intervention) |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention · arms resolved
99 people have samples in more than one arm.
Prebiotic / dietary fibre supplement design randomized_controlled_trial · population liver_disease · Resistant starch supplementation vs placebo, 16 weeks, in NAFLD patients
“randomized, placebo-controlled, double-blinded clinical trial of resistant starch” — bioproject.description (study level; per-sample arms are in the intervention column below)
longitudinal — not resolved
116 of 136 people sampled more than once (232 samples; median 2, up to 2 per person). Schedule stated by the source: “Each subject sampled at visit 1 (V1, baseline) and visit 5 (V5, end of 16-week intervention), per sample titles/aliases” (time origin: intervention start (visit 1)); stated follow-up 4 mo.
Genera, mean relative abundance over 234 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 0 | 0% | ||||
| country | 252 | 100% | 252 | |||
| health_condition | 252 | 100% | 252 | |||
| subject_id | 252 | 100% | 252 | |||
| collection_date | 252 | 100% | 252 | |||
| detailed_location | 252 | 100% | ||||
| health_condition_detail | 252 | 100% | 252 | |||
| latitude | 252 | 100% | 252 | |||
| location_locality | 252 | 100% | 252 | |||
| location_region | 252 | 100% | 252 | |||
| longitude | 252 | 100% | 252 | |||
| timepoint_label | 252 | 100% | 252 | |||
| intervention | 207 | 82% | 199 | 8 |
- Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations 2023 PMID 37673036 own_data
- Risk assessment with gut microbiome and metabolite markers in NAFLD development. 2022 PMID 35675435 PMC9746350 unsure
- Identification of robust and generalizable biomarkers for microbiome-based stratification in lifestyle interventions. 2023 PMID 37553697 PMC10408196 unsure
- Discovery of robust and highly specific microbiome signatures of non-alcoholic fatty liver disease. 2025 PMID 39810263 PMC11730835 unsure
Archive description
The addition of resistant starch (RS) to the diet has been proven to ameliorate the condition of patients with NAFLD related diseases such as prediabetes and obesity, but until now, no clinical studies have been focused on NAFLD subjects. In this study, we performed a randomized, placebo-controlled, double-blinded clinical trial of resistant starch in NAFLD patients. By integrating targeted metabolomic profiling and shotgun metagenomic sequencing, we characterised the molecular changes of host and gut microbiota metabolic products upon 16-week RS intervention, as well as the variation of patients gut microbiota structure and function.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by opus_adjudicated with confidence 0.85. Assay shotgun_dna.
- host run.host_tax_id · “9606”
- host study.title · “Human gut microbiota raw sequence reads”
- body site study.title · “Human gut microbiota”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN18023147 | collection_date | 2017 | R1 | 0.90 | biosample.attribute:collection_date | 2017 |
| SAMN18023147 | country | CN | R1 | 0.90 | sample.attr.geo_loc_name | China: Shanghai |
| SAMN18023147 | health_condition | other_disease | R4 | 0.50 | study.title | resistant starch intervention project in patients with NAFLD |
| SAMN18023147 | health_condition_detail | Non-alcoholic fatty liver disease (NAFLD) | R4 | 0.50 | paper.abstract | randomized placebo-controlled clinical trial in individuals with NAFLD |
| SAMN18023147 | intervention | no_intervention | R1 | 0.70 | sample.name_rule:alias | alias: CS008V1 |
| SAMN47418225 | intervention | diet_intervention | R2 | 0.75 | paper.supp.40168_2023_1604_MOESM1_ESM.docx[table7!col0] | I_HFD |
| SAMN18023147 | latitude | 31.1883 | R1 | 0.90 | biosample.attribute:lat_lon | 31.1883 N 121.4368 E |
| SAMN18023147 | location_locality | Shanghai | R1 | 0.85 | biosample.attribute:geo_loc_name | China: Shanghai |
| SAMN18023147 | location_region | Shanghai Shi | R1 | 0.60 | biosample.attribute:lat_lon | 31.1883 N 121.4368 E |
| SAMN18023147 | longitude | 121.4368 | R1 | 0.90 | biosample.attribute:lat_lon | 31.1883 N 121.4368 E |
| SAMN18023147 | subject_id | 008 | R1 | 0.70 | sample.name_rule:alias | alias: CS008V1 |
| SAMN18023147 | timepoint_label | V1 | R1 | 0.70 | sample.name_rule:alias | alias: CS008V1 |
Sequencing
252 runs over 252 samples · mean 6.20 Gbp per run (median 6.17 Gbp, total 1,561.35 Gbp; 252 runs with a base count) · layout PAIRED 252 · platform ILLUMINA 252 · models Illumina NovaSeq 6000 (252) · 93% of runs with a Sandpiper profile · first public 2022-01-01 – 2025-11-29
Authors (36)
Leung H first · Long X · Ni Y · Qian L · Nychas E · Siliceo SL · Pohl D · Hanhineva K · Liu Y · Xu A · Nielsen HB · Belda E · Clément K · Loomba R · Li H · Jia W · Panagiotou G last · Chen J first · Ismaiah MJ · Zhang L · Gao Q · Wu Q · Zhang Y · Jia X · Liu S · Yuan R · Zhou L · Wang X · Li Q · Zhao Y · El-Nezami H · Xu G · Marfil-Sánchez A · Chen X · Mirhakkak M · Nieuwdorp M
Downloads
PRJNA703757.csv.gz (7.4 KB) · parquet (80.6 KB) — all 252 samples, every field with route and confidence · PRJNA703757_determinations.csv.gz (23.4 KB) — 2,727 evidence rows